ShRNA interference for extracellular signal-regulated kinase 2 can inhibit the growth of esophageal cancer cell line Eca109

Journal of Receptors and Signal Transduction

Volumn 30, Issue 3, 2010, Pages 170-177

  Huo, Qi ^a   Zheng, Shu Tao ^a   Tuersun, Aerziguli ^a   Huang, Cong Gai ^a   Liu, Qing ^a   Zhang, Xue ^a   Sheyhidin, Ilyar ^a   Lu, Xiao Mei ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

ERK2; Esophageal cancer; MAPK; ShRNA

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CONTROLLED STUDY; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; RNA INTERFERENCE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE 2; MICROSCOPY, FLUORESCENCE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION;

EID: 77951628238     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799891003786200     Document Type: Article

References (26)

1. Parkin DM, Bray FI, Devesa SS.Cancer burden in the year 2000 the global picture. Eur J Cancer 2001, 37, S4S66.
2. Stoner GD, Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001, 22, 1737-1746. (Pubitemid 33064837)
3. Stoner GD, Wang LS, Chen T. Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol 2007, 224, 337-349.
4. Umar SB, Fleischer DE. Esophageal cancer: epidemiology, patho-genesis and prevetion. Gastroen Hepatology 2008, 5, 517-526.
5. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008, 22, 954-965.
6. McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26, 3113-3121.
7. Zeng PY, Wagoner HA, Pescovitz OH, Steinmet R. RNA interference (RNAi) for extracellular signal-regulated kinase 1 (ERK1) alone is sufcient to suppress cell viability in ovarian cancer cells. Cancer Biol Ter 2005, 4, 961-967.
8. Bhalla US, Ram P T, Iyengar R. MAP kinase phosphatase as a locus of fexibility in a mitogen-activated protein kinase signaling network. Science 2002, 297, 1018-1023.
9. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003, 63, 756-759.
10. Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK, O'Sullivan GC. Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem 2001, 276, 15537-15546.
11. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 1997, 99, 1478-1483.
12. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Difer 2001, 12, 397-408.
13. Kamakura S, Moriguchi T, Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identifcation and characterization of a signaling pathway to the nucleus. J Biol Chem 1999, 274, 26563-26571.
14. Frémin C, Ezan F, Boisselier P, Bessard A, Pagès G, Pouysségur J, Bafet G. ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. Hepatology 2007, 45, 1035-1045.
15. Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Multiple anticancer efects of blocking MEK-ERK signal-ing in hepatocellular carcinoma. J Am Coll Surg 2004, 198, 410-421.
16. Bessard A, Frémin C, Ezan F, Coutant A, Bafet G. MEK/ERK-dependent uPAR expression is required for motility via phos-phorylation of P70S6K in human hepatocarcinoma cells. J Cell Physiol 2007, 212, 526-536.
17. Liu X, Yan S, Zhou T, Terada Y, Erikson RL. Te MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 2004, 23, 763-776.
18. Shama J, Garcia-Medina R, Pouyssegur J, Vial E. Major contribution of MEK1 to the activation of ERK1/ERK2and to the growth of LS174T colon carcinoma cells. Biochem Bioph Res Co 2008, 372, 845-849.
19. Lefoch R, Pouysségur J, Lenormand P. Single and combined silencing of ERK1 and ERK2reveals their positive contribution to growth signaling depending on their expression levels. Mol Cel Biol 2008, 28, 511-527.
20. Lawrence MC, Jivan A, Shao CL, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, Chen W, Cobb MH. Te roles of MAPKs in diease. Cell Res 2008, 18, 436-442.
21. Daoud G, Amyot M, Rassart E, Masse A, Simoneau L, Lafond J. ERK1/2 and p38 regulate trophoblasts diferentiation in human term placenta. J Physiol (Lond) 2005, 566, 409-423.
22. Carthew RW. Gene silencing by double-stranded RNA. Curr Opin Cell Biol 2001, 13, 244-248.
23. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002, 20, 446-448.
24. Sui G, Soohoo C, Afar EB, Gay F, Shi Y, Forrester WC, Shi Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002, 99, 5515-5520.
25. Tang F, Meng G, Yang H, Li CJ, Shi Y, Ding M, Shang KG, Zhang B, Xue Y. Stable suppression of gene expression in murine embryonic stem cells by RNAi directed from DNA vector-based short hairpin RNA. Stem Cell 2004, 22, 93-99.
26. Novrino G. Involvement of the intracellular ion channel CLIC1 in microglia-mediated β-amyloid-induced neurotoxicity. J Neurosci 2004, 24, 5322-5330.